p21 anticorps

N° du produit ABIN967445

Détail du produit anti-p21 anticorps

Antigène: p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp p21 est non-conjugé

Application: Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Immunoprecipitation (IP), Immunohistochemistry (Frozen Sections) (IHC (fro))

Marque: BD Pharmingen™

Attributs du produit: 1. Since applications vary, each investigator should titrate the reagent to obtain optimal results.
2. Please refer to us for technical protocols.
3. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.

Purification: The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography.

Immunogène: Human p21

Clone: 6B6

Isotype: IgG1

Information d'application

Indications d'application: Applications include immunoprecipitation (1-2 µg/1x10^6 cells), western blot analysis (1-2 µg/ml) and immunohistochemistry of paraformaldehyde-fixed cultured cells (0.5-2.5 µg/ml) and acetone-fixed, frozen and formalin-fixed paraffin-embedded (10 µg/ml) tissue sections. MCF7 human breast carcinoma cells (ATCC HTB-22) are suggested as a positive control. WI-38 human lung fibroblasts (ATCC CCL-75) treated with doxorubin (Adriamycin) can also be used as a positive control.

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: Aqueous buffered solution containing ≤0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Stock: 4 °C

Stockage commentaire: Store undiluted at 4°C.

Références pour anticorps anti-p21 (ABIN967445)

Clarke, Lotz, Chao, Mercurio: "Activation of the p21 pathway of growth arrest and apoptosis by the beta 4 integrin cytoplasmic domain." dans: The Journal of biological chemistry, Vol. 270, Issue 39, pp. 22673-6, (1995) (PubMed).

Halevy, Novitch, Spicer, Skapek, Rhee, Hannon, Beach, Lassar: "Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD." dans: Science (New York, N.Y.), Vol. 267, Issue 5200, pp. 1018-21, (1995) (PubMed).

el-Deiry, Harper, OConnor, Velculescu, Canman, Jackman, Pietenpol, Burrell, Hill, Wang: "WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis." dans: Cancer research, Vol. 54, Issue 5, pp. 1169-74, (1994) (PubMed).

Hunter: "Braking the cycle." dans: Cell, Vol. 75, Issue 5, pp. 839-41, (1994) (PubMed).

Noda, Ning, Venable, Pereira-Smith, Smith: "Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen." dans: Experimental cell research, Vol. 211, Issue 1, pp. 90-8, (1994) (PubMed).

Xiong, Hannon, Zhang, Casso, Kobayashi, Beach: "p21 is a universal inhibitor of cyclin kinases." dans: Nature, Vol. 366, Issue 6456, pp. 701-4, (1994) (PubMed).

el-Deiry, Tokino, Velculescu, Levy, Parsons, Trent, Lin, Mercer, Kinzler, Vogelstein: "WAF1, a potential mediator of p53 tumor suppression." dans: Cell, Vol. 75, Issue 4, pp. 817-25, (1993) (PubMed).

Détails sur p21

Antigène: p21 (CDKN1A) (Cyclin-Dependent Kinase Inhibitor 1A (p21, Cip1) (CDKN1A))

Autre désignation: p21 (CDKN1A Produits)

Synonymes: anticorps CCND1, anticorps CDKN1A, anticorps CAP20, anticorps CDKN1, anticorps CIP1, anticorps MDA-6, anticorps P21, anticorps SDI1, anticorps WAF1, anticorps p21CIP1, anticorps CDKI, anticorps Cdkn1, anticorps Waf1, anticorps mda6, anticorps p21Cip1, anticorps p21WAF, anticorps Cip1, anticorps UV96, anticorps p21, anticorps cip1, anticorps p16Xic2, anticorps sdi1, anticorps waf1, anticorps cap20, anticorps cdkn1, anticorps mda-6, anticorps p21cip1, anticorps si:ch1073-48m5.2, anticorps KRAS2, anticorps p21ras, anticorps cyclin D1, anticorps cyclin dependent kinase inhibitor 1A, anticorps cyclin-dependent kinase inhibitor 1A (P21), anticorps cyclin-dependent kinase inhibitor 1A, anticorps cyclin-dependent kinase inhibitor 1A L homeolog, anticorps cyclin-dependent kinase inhibitor 1, anticorps KRAS proto-oncogene, GTPase, anticorps CCND1, anticorps CDKN1A, anticorps Cdkn1a, anticorps cdkn1a.L, anticorps cki1, anticorps cdkn1a, anticorps KRAS

Sujet: P21 belongs to a class of tumor suppressors including p16 and p27 which control progression through the cell cycle by inhibiting the activity of cyclin-cdk complexes. p21 is also known as senescent cell-derived inhibitor 1 (Sdi1), wild-type p53-activated fragment 1 (Waf1), Cdk-interacting protein 1 (Cip1), p21 and p53-regulated inhibitor of Cdks (Pic1). p21 mRNA is expressed at higher levels in senescent fibroblasts than in actively growing cells. When introduced into proliferating foreskin fibroblasts, p21 inhibits DNA synthesis and cell cycle arrest. p53 can activate p21 gene expression via a p53 binding site identified in the promoter of the p21 gene.

Poids moléculaire: 21 kDa

Pathways: Signalisation p53, Signalisation PI3K-Akt, Cycle Cellulaire, AMPK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Mitotic G1-G1/S Phases, DNA Replication, Hepatitis C, Synthesis of DNA, Autophagy